Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

被引：0
|
作者：
Caffo, O. [1 ]
Palesandro, E. [2 ]
Nole, F. [3 ]
Gasparro, D. [4 ]
Mucciarini, C. [5 ]
Aieta, M. [6 ]
Zagonel, V. [7 ]
Iacovelli, R. [8 ]
De Giorgi, U. F. F. [9 ]
Rossetti, S. [10 ]
Fratino, L. [11 ]
Ermacora, P. [12 ]
Nicodemo, M. [13 ]
Giordano, M. [14 ]
Sartori, D. [15 ]
Scapoli, D. [16 ]
Verri, E. [3 ]
Maines, F. [17 ]
Pappagallo, G.
Aglietta, M. [18 ]
机构：
[1] Osped Santa Chiara, Med Oncol, Trento, Italy
[2] IRCCS Candiolo, Dipartimento Oncol Med, Candiolo, Italy
[3] Ist Europeo Oncol, Med Oncol, Milan, Italy
[4] AOU Parma, Med Oncol, Parma, Italy
[5] Osped Ramazzini, Med Oncol, Carpi, Italy
[6] Ctr Riferimento Oncol Basilicata IRCCS, Med Oncol, Rionero In Vulture, Italy
[7] Ist Oncol Veneto IRCCS, Med Oncol, Padua, Italy
[8] Fdn Policlin Agostino Gemelli, IRCCS, Rome, Italy
[9] Ist Tumori Romagna IRST, Dept Med Oncol, Meldola, Forli Cesena, Italy
[10] Fdn Pascale, Unita Dipartimentale Uroandrol, Naples, Italy
[11] CRO, Med Oncol, Aviano, Italy
[12] AOU Udine, Med Oncol, Udine, Italy
[13] Negrar Canc Ctr, Med Oncol, Negrar, Italy
[14] Presidio Osped Osped St Anna, Med Oncol, San Fermo Battaglia, Italy
[15] Osped Civiile Dolo, Med Oncol, Dolo, Italy
[16] Azienda Osped Ferrara St Anna, Med Oncol, Ferrara, Italy
[17] Osped Santa Chiara, Oncol, Trento, Italy
[18] Ist Candiolo FPO IRCCS, Med Oncol, Candiolo, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
854P
引用
收藏
页码：333 / 333
页数：1
相关论文
共 50 条
  • [41] Docetaxel (D) plus estramustine (E) versus D alone in patients (pts) with hormone-refractory prostate cancer (HRPC): Updated analysis of a phase II randomized trial
    Mousseau, Mireille
    Joly, Florence
    Priou, Franck
    Zannetti, Alain
    Ravaud, Alain
    Kerbrat, Pierre
    Paule, Bernard
    Touze, Florence
    Ecstein-Fraisse, Evelyne
    Eymard, Jean-Christophe
    ANNALS OF ONCOLOGY, 2004, 15 : 114 - 114
  • [42] The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer
    Park, Jong Chul
    Pratz, Caroline F.
    Tesfaye, Anteneh
    Brodsky, Robert A.
    Antonarakis, Emmanuel S.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (01) : 32 - 38
  • [43] Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
    Graff, Julie Nicole
    Cheng, Heather H.
    Vuky, Jacqueline
    Alumkal, Joshi J.
    Kreitner, Dustin
    Petreaca, Delia
    Grivas, Petros
    Schweizer, Michael Thomas
    Higano, Celestia S.
    Chen, Yiyi
    Yu, Evan Y.
    Beer, Tomasz M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [44] Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2018, 199 (04): : 893 - 894
  • [45] Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC)
    Serritella, Anthony
    Shevrin, Daniel H.
    Heath, Elisabeth I.
    Wade, James Lloyd
    Martinez, Elia
    Karrison, Theodore
    Stadler, Walter Michael
    Szmulewitz, Russell Zelig
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [46] Real-world comparison of abiraterone (A) versus enzalutamide (E) for first-line therapy of metastatic castration-resistant prostate cancer (mCRPC).
    Briones, Carvajal
    Juan, Rodrigo
    Naimi, Mahdi Farzad
    Zhang Liying
    Emmenegger, Urban
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [47] Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure
    Meulenbeld, Hielke J.
    Bleuse, Jean P.
    Vinci, Elio M.
    Raymond, Eric
    Vitali, Giordano
    Santoro, Armando
    Dogliotti, Luigi
    Berardi, Rossana
    Cappuzzo, Federico
    Tagawa, Scott T.
    Sternberg, Cora N.
    Jannuzzo, Maria G.
    Mariani, Mariangela
    Petroccione, Anna
    de Wit, Ronald
    BJU INTERNATIONAL, 2013, 111 (01) : 44 - 52
  • [48] A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial
    Bouman-Wammes, Esther W.
    van den Berg, H. Pieter
    de Munck, Linda
    Beeker, Aart
    Smorenburg, Carolien H.
    Vervenne, Walter L.
    Coenen, Juleon L. L. M.
    Verheul, Henk M. W.
    Gerritsen, Winald R.
    Van den Eertwegh, Alfons J. M.
    EUROPEAN JOURNAL OF CANCER, 2018, 90 : 1 - 9
  • [49] Bis docetaxel (D) ± estramustine (E) as first line chemotherapy for patients (PTS) with hormone-refractory advanced prostate cancer (HRPC).: A multicentric Italian phase II randomized trial
    Caffo, O.
    Sava, T.
    Comploj, E.
    Zustovich, F.
    Mansueto, G.
    Segati, R.
    Sacco, C.
    Perin, A.
    Frisinghelli, M.
    Valduga, F.
    Galligioni, E.
    ANNALS OF ONCOLOGY, 2006, 17 : XI80 - XI80
  • [50] Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen
    Eisenberger, Mario A.
    Hardy-Bessard, Anne-Claire
    Mourey, Loic
    Mainwaring, Paul N.
    Ford, Daniel
    Shapiro, Jeremy David
    Carles, Joan
    Ng, Siobhan
    Gil, Thierry
    Alekseev, Boris
    Ivanov, Sergey
    Facchini, Thomas
    Legouffe, Eric
    Apolikhin, Oleg
    Pandha, Hardev S.
    Beeker, Aart
    Karyakin, Oleg
    Zhang, Wendy
    Chadjaa, Mustapha
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345